Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniele Mengato

Showing results (1-10 of 91) with videos related to

Pageof 10
Sort By:
Clinical and Experimental Rheumatology|March 31, 2018
Adalimumab biosimilar in rheumatoid arthritis: a total-evidence assessment to evaluate equivalence with the originator based on network meta-analysisDaniele Mengato, Andrea Messori
European Journal of Hospital Pharmacy : Science and Practice|June 29, 2021
'To crush or not to crush, that is the question!' An algorithm can help with the proper administration of solid oral medicines in patients where the oral route is compromisedNicolas Sagaria, Daniele Mengato
Therapeutic Advances in Medical Oncology|August 3, 2016
Pricing of innovative drugs: correlation between incremental cost and survival gain in four countriesDaniele Mengato, Andrea Messori
European Journal of Hospital Pharmacy : Science and Practice|April 14, 2021
Hand hygiene for healthcare workers: did we need COVID-19 to raise awareness of proper disinfection practice?Daniele Mengato, Lorenzo Di Spazio
Clinical Therapeutics|December 12, 2022
Chimeric Antigen Receptor T Cells in Large B-Cell Lymphoma: Analysis of Overall Survival Based on Reconstructed Patient-Level DataAndrea Messori, Marco Chiumente, Daniele Mengato
Journal of Gastrointestinal Cancer|January 18, 2022
Adjuvant Nivolumab in Esophageal or Gastroesophageal Junction Cancer: the Improvement in Progression-Free Survival Is SmallDaniele Mengato, Marco Chiumente, Andrea Messori
Haematologica|September 23, 2017
Rituximab biosimilar evaluated by network meta-analysisMarco Chiumente, Daniele Mengato, Andrea Messori
International Journal of Clinical Pharmacology and Therapeutics|December 22, 2018
Trastuzumab biosimilar in metastatic breast cancer: Evaluating equivalence with originator using network meta-analysis
Daniele Mengato, Marco Chiumente, Andrea Messori
Acta Haematologica|February 20, 2020
Tisagenlecleucel in Non-Hodgkin Lymphoma: The Restricted Mean Survival Time as a Tool for Estimating Progression-Free Life Expectancy Better than the MedianMarco Chiumente, Daniele Mengato, Andrea Messori
JAMA Cardiology|March 2, 2022
Age-Adjusted Survival Extrapolations-Results May Differ From Those Generated by the Weibull ModelAndrea Messori, Daniele Mengato, Marco Chiumente
Pageof 10

Showing results (1-10 of 91) with videos related to

Sort By:
Pageof 10
Clinical and Experimental Rheumatology|March 31, 2018
Adalimumab biosimilar in rheumatoid arthritis: a total-evidence assessment to evaluate equivalence with the originator based on network meta-analysisDaniele Mengato, Andrea Messori
European Journal of Hospital Pharmacy : Science and Practice|June 29, 2021
'To crush or not to crush, that is the question!' An algorithm can help with the proper administration of solid oral medicines in patients where the oral route is compromisedNicolas Sagaria, Daniele Mengato
Therapeutic Advances in Medical Oncology|August 3, 2016
Pricing of innovative drugs: correlation between incremental cost and survival gain in four countriesDaniele Mengato, Andrea Messori
European Journal of Hospital Pharmacy : Science and Practice|April 14, 2021
Hand hygiene for healthcare workers: did we need COVID-19 to raise awareness of proper disinfection practice?Daniele Mengato, Lorenzo Di Spazio
Clinical Therapeutics|December 12, 2022
Chimeric Antigen Receptor T Cells in Large B-Cell Lymphoma: Analysis of Overall Survival Based on Reconstructed Patient-Level DataAndrea Messori, Marco Chiumente, Daniele Mengato
Journal of Gastrointestinal Cancer|January 18, 2022
Adjuvant Nivolumab in Esophageal or Gastroesophageal Junction Cancer: the Improvement in Progression-Free Survival Is SmallDaniele Mengato, Marco Chiumente, Andrea Messori
Haematologica|September 23, 2017
Rituximab biosimilar evaluated by network meta-analysisMarco Chiumente, Daniele Mengato, Andrea Messori
International Journal of Clinical Pharmacology and Therapeutics|December 22, 2018
Trastuzumab biosimilar in metastatic breast cancer: Evaluating equivalence with originator using network meta-analysis
Daniele Mengato, Marco Chiumente, Andrea Messori
Acta Haematologica|February 20, 2020
Tisagenlecleucel in Non-Hodgkin Lymphoma: The Restricted Mean Survival Time as a Tool for Estimating Progression-Free Life Expectancy Better than the MedianMarco Chiumente, Daniele Mengato, Andrea Messori
JAMA Cardiology|March 2, 2022
Age-Adjusted Survival Extrapolations-Results May Differ From Those Generated by the Weibull ModelAndrea Messori, Daniele Mengato, Marco Chiumente
Pageof 10